首页 | 本学科首页   官方微博 | 高级检索  
     


High-Throughput Massively Parallel Sequencing for Fetal Aneuploidy Detection from Maternal Plasma
Authors:Taylor J. Jensen  Tricia Zwiefelhofer  Roger C. Tim   ?eljko D?akula  Sung K. Kim  Amin R. Mazloom  Zhanyang Zhu  John Tynan  Tim Lu  Graham McLennan  Glenn E. Palomaki  Jacob A. Canick  Paul Oeth  Cosmin Deciu  Dirk van den Boom  Mathias Ehrich
Affiliation:1. Research and Development, Sequenom Center for Molecular Medicine, San Diego, California, United States of America.; 2. Research and Development, Sequenom Inc., San Diego, California, United States of America.; 3. Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.; Tel Aviv University, Israel,
Abstract:

Background

Circulating cell-free (ccf) fetal DNA comprises 3–20% of all the cell-free DNA present in maternal plasma. Numerous research and clinical studies have described the analysis of ccf DNA using next generation sequencing for the detection of fetal aneuploidies with high sensitivity and specificity. We sought to extend the utility of this approach by assessing semi-automated library preparation, higher sample multiplexing during sequencing, and improved bioinformatic tools to enable a higher throughput, more efficient assay while maintaining or improving clinical performance.

Methods

Whole blood (10mL) was collected from pregnant female donors and plasma separated using centrifugation. Ccf DNA was extracted using column-based methods. Libraries were prepared using an optimized semi-automated library preparation method and sequenced on an Illumina HiSeq2000 sequencer in a 12-plex format. Z-scores were calculated for affected chromosomes using a robust method after normalization and genomic segment filtering. Classification was based upon a standard normal transformed cutoff value of z = 3 for chromosome 21 and z = 3.95 for chromosomes 18 and 13.

Results

Two parallel assay development studies using a total of more than 1900 ccf DNA samples were performed to evaluate the technical feasibility of automating library preparation and increasing the sample multiplexing level. These processes were subsequently combined and a study of 1587 samples was completed to verify the stability of the process-optimized assay. Finally, an unblinded clinical evaluation of 1269 euploid and aneuploid samples utilizing this high-throughput assay coupled to improved bioinformatic procedures was performed. We were able to correctly detect all aneuploid cases with extremely low false positive rates of 0.09%, <0.01%, and 0.08% for trisomies 21, 18, and 13, respectively.

Conclusions

These data suggest that the developed laboratory methods in concert with improved bioinformatic approaches enable higher sample throughput while maintaining high classification accuracy.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号